Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Garp1on Jul 14, 2015 7:33am

123 Views

Post# 23920834

RE:Egrifta approved in Mexico

Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that COFEPRIS, Mexico's health agency, has approved the 2mg/vial presentation of tesamorelin for the treatment of lipodystrophy. Theratechnologies' partner, sanofi, will re-submit a file to COFEPRIS to seek approval of the 1mg/vial presentation of EGRIFTA which is the one currently marketed in other territories. As was the case with Canada, the commercialization of EGRIFTA in Mexico will be initiated upon obtaining approval of the 1mg/vial presentation

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading